ArticleJACC. Case reports2026
Apolipoprotein A-IV Cardiac Amyloidosis as a Diagnostic Pitfall: Beyond the Noninvasive Algorithm.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac amyloidosis is frequently underdiagnosed, and rarer forms (eg, nontransthyretin amyloidosis, light chain amyloidosis) can be challenging to uncover. CASE SUMMARY: A 71-year-old man with reduced kidney function presented with new-onset heart failure, concentric left ventricular hypertrophy, and an "apical sparing" strain pattern. Cardiac magnetic resonance confirmed an infiltrative phenotype with suggestive late gadolinium enhancement and parametric mapping pattern. However, bone scintigraphy and monoclonal protein screening were negative; therefore, an endomyocardial biopsy was performed. After negative immunohistochemistry, mass spectrometry-based proteomics finally identified apolipoprotein A-IV amyloidosis. DISCUSSION: Apolipoprotein A-IV cardiac amyloidosis represents a critical diagnostic blind spot and requires molecular proteomics for definitive typing. TAKE-HOME MESSAGES: A pathognomonic cardiac magnetic resonance phenotype for cardiac amyloidosis, despite negative bone scintigraphy and monoclonal protein screening, should prompt invasive investigation to identify rare amyloid types. Endomyocardial biopsy with mass spectrometry remains the definitive diagnostic technique for amyloid typing in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.